New Tools for Studying Vesicular-Mediated Protein Trafficking: Synthesis and Evaluation of Ilimaquinone Analogs in a Non-Radioisotope-Based Antisecretory Assay

Heike S. Radeke, Cheryl A. Digits,¹ Steven D. Bruner,² and Marc L. Snapper*

Eugene F. Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02167-3860

Received December 9, 1996[®]

Structural variants of the marine sponge metabolite ilimaquinone, with comparable biological activity, have been prepared. These analogs, as well as related natural products, were screened for their effects on the Golgi apparatus through a novel, non-radioisotope-based secretion assay. The assay has identified a variant of ilimaquinone that contains a versatile linker group yet retains the natural product's cellular activity. This functional ilimaquinone analog will be a valuable tool for studying intracellular protein trafficking.

Introduction

Ilimaquinone³ (1) and related sesquiterpene quinones, such as avarone⁴ (2), are reported to have interesting biological effects including antimicrobial, anti-HIV, antiinflammatory, and antimitotic activity.⁵ More recently, ilimaquinone's ability to inhibit the cytotoxicity of ricin and diphtheria toxin,⁶ as well as to reversibly disrupt the Golgi apparatus, has also been noted.⁷ Considering the proven value of using natural products as probes of cellular processes,⁸ our plan is to exploit ilimaquinone's unique activity for the study of intracellular vesicular trafficking.



A crucial element in our plan is the design and preparation of an active variant of ilimaquinone that



Figure 1. Modifications to ilimaquinone.

contains a versatile linker group. Such a compound will allow us to probe vesicular trafficking through a variety of protein isolation techniques including affinity chromatography, photoaffinity labeling, and ligand blotting experiments.⁹ In this regard, our studies on the synthesis of (–)-ilimaquinone and related compounds are reported herein. In addition, the development of a novel, non-radioisotope-based antisecretion assay to evaluate the ilimaquinone analogs is also described. The combined synthetic and biochemical effort has allowed for the identification of an active analog possessing the functionality required to study ilimaquinone's role in vesicular trafficking.

Results and Discussion

Synthesis. Given that the shortest route to a compound with the functionality required for our studies might be realized through direct modification of ilimaquinone, our initial chemical efforts focused on derivatizing the natural product. This strategy was supported by the fact that several variants of ilimaquinone's quinone moiety have already been reported (Figure 1, **3** and **4**).^{3a,5a} Nevertheless, to increase the likelihood of identifying a useful compound, additional analogs were sought. To this end, (–)-ilimaquinone was oxidized with SeO₂/*t*-BuOOH to introduce a hydroxyl at the C3 position

^{*} Corresponding author: phone, (617) 552-8096; fax, (617) 552-0230; e-mail, marc.snapper@BC.edu.

[®] Abstract published in Advance ACS Abstracts, April 1, 1997.

⁽¹⁾ Department of Education GAANN Fellow.

⁽²⁾ Boston College Undergraduate Research Fellow.

^{(3) (}a) Luibrand, R. T.; Erdman, T. R.; Vollmer, J. J.; Scheuer, P. J.; Finer, J.; Clardy, J. C. *Tetrahedron* **1979**, *35*, 609. (b) Capon, R. J.;

MacLeod, J. K. J. Org. Chem. **1987**, 52, 5060. (4) Minale, L.; Riccio, R.; Sodano, G. Tetrahedron Lett. **1974**, 38,

 $[\]begin{array}{c} (4) \text{ Minuce, E., Receiv, R., Southo, G. Petranculov Ect. 1044, 55 \\ (5) \\ ($

^{(5) (}a) Loya, S.; Tal, R.; Kashman, Y.; Hizi, A. Antimicrob. Agents Chemother. **1990**, 34, 2009. (b) Kushlan, D. M.; Faulkner, D. J.; Parkanyi, L.; Clardy, J. C. Tetrahedron **1989**, 45, 3307. (c) Bourguet-Kondracki, M.-L.; Longeon, A.; Morel, E.; Guyot, M. Int. J. Immunopharmacol. **1991**, 13, 393. (d) Schröder, H. C.; Wenger, R.; Gerner, H.; Reuter, P.; Kuchino, Y.; Sladic, D.; Müller, W. E. G. Cancer Res. **1989**, 49, 2069. (e) Sarin, P. S.; Sun, D.; Thornton, A.; Müller, W. E. G. J. Natl. Cancer Inst. **1987**, 78, 663. (f) Belisario, M. A.; Maturo, M.; Pecce, R.; De, R. S.; Villani, G. R. D. Toxicology **1992**, 72, 221. (g) Müller, W. E. G.; Dogovic, N.; Zahn, R. K.; Maidhof, A.; Diehl, S. B.; Bedker, C.; Sachsse, W.; Gasic, M. J.; Schroeder, H. C. Basic Appl. Histochem. **1985**, 29, 321.

⁽⁶⁾ Nambiar, M. P.; Wu, H. C. Exp. Cell Res. 1995, 219, 671.

^{(7) (}a) Talizawa, P. A.; Yucel, J. K.; Veit, B.; Faulkner, D. J.; Deerinck, T.; Soto, G.; Ellisman, M.; Malhotra, V. *Cell* **1993**, *73*, 1079.

⁽b) Veit, B.; Yucel, J. K.; Malhotra, V. J. Biol. Chem. 1993, 12, 1197.
(8) (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. Acc. Chem. Res. 1993, 26, 412. (b) Schreiber, S. L. Chem. Eng. News 1992, 70 (Oct. 26), 22.

⁽⁹⁾ For example, see: (a) Jones, K. Am. Biotechnol. Lab. **1990**, 8, 26. (b) Fretz, H.; Albers, M. W.; Galat, A.; Standaert, R. F.; Lane, W. S.; Burakoff, S. J.; Bierer, B. E.; Schreiber, S. L. J. Am. Chem. Soc. **1991**, 113, 1409. (c) Wilchek, M.; Bayer, E. A. Methods Enzymol. **1990**, 184, 243. (d) Wade, D. P.; Knight, B. L.; Soutar, A. K. Biochem. J. **1985**, 229, 785. (e) Morris, D. I.; Robbins, J. D.; Ruoho, A. E.; Sutkowski, E. M.; Seamon, K. B. J. Biol. Chem. **1991**, 266, 13377. For additional experiments, see: (f) Handschumacher, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D. W. Science **1984**, 226, 544. (g) Shen, G. K.; Zukoski, C. F.; Montgomery, D. W. Int. J. Immunopharmacol. **1992**, 14, 63. (h) Siekierka, J. J.; Staruch, M. J.; Hung, S. H.; Sigal, N. H. J. Immunol. **1989**, 143, 1580.



^{*a*} Key: (a) Li⁰, NH₃, 3,5-dimethoxybenzyl bromide (57%); (b) $Ph_3P=CH_2$, DMSO (60%); (c) H_2 , Pd/C (84%); (d) PCC, CH_2Cl_2 (94%); (e) $Ph_3P=CH_2$, DMSO (71%); (f) CrO_3 (68%); (g) AcOH, NaOAc, H_2O (86%); (h) FeCl₃, H_2O .

(94% yield). The C3 hydroxyl group was then esterified with BOC-protected 6-aminohexanoic acid (84% yield) to provide compound **5**. If active, this variant of ilimaquinone (**5**) with a tethered linker group should be an effective tool for our studies. Unfortunately, our activity assay (see assay results) indicated that **5** retains none of ilimaquinone's influence on protein trafficking (*i.e.*, vesicular-mediated protein secretion). While additional modifications to ilimaquinone are possible, insufficient supplies of the natural product precluded further synthetic investigations.

A more plentiful source of analogs should be available through synthesis from readily available starting materials. Our initial approach to (–)-ilimaquinone, which was modeled after Sarma's preparation of (\pm)-avarone¹⁰ (**2**), is illustrated in Scheme 1. Unfortunately, reactions to install the necessary quinone functionality did not provide the expected results.¹¹

We anticipated that a Thiele–Winter acetoxylation of **9**¹² followed by treatment of the resulting triacetoxyaryl moiety with LAH and mild oxidation would provide (–)-ilimaquinone.¹³ Unfortunately, the acetoxylation reaction resulted in low mass recovery which, in part,

(12) McOmie, J. F. W.; Blatchly, J. M. Org. React. 1972, 19, 199.
(13) For recent examples of this sequence in related systems, see:
(a) Sargent, M. V.; Wangchareontrakul, S. J. Chem. Soc. Perkin Trans. J 1990, 1429.
(b) Almeida, W. P.; Correia, C. R. D. Tetrahedron Lett. 1994, 35, 1367.



^a Key: (a) Li⁰, NH₃, 2-chloro-3,5-dimethoxybenzyl bromide (75%); (b) Ph₃P=CH₂, DMSO (71%); (c) H₂, PtO₂, CH₂Cl₂ (60%); (d) PCC, CH₂Cl₂ (95%); (e) Ph₃P=CH₂, DMSO (82%); (f) CAN, CH₃CN, H₂O (72%); (g) Pd(Ph₃P)₄, THF, H₂O, NaHCO₃ (33%).

involved a migration of the $\Delta^{4,11}$ olefin.¹⁴ In retrospect, this is not surprising given the strong acidic conditions of the Thiele–Winter acetoxylation (H₂SO₄).

When the acidity problem was circumvented by treating **9** with sodium acetate in acetic acid, clean addition of acetate into the quinone system was observed. However, subsequent acetylation of this acetate addition product (**10a**) did not yield compound **3**, an intermediate derived from the natural product. A NOE study of the quinone/aromatic protons in the unidentified product, as well as in compound **9**, indicated that the compound obtained in the acetate addition is **10a**, not the required acetate regioisomer **10b**. Apparently, steric factors override the electronic biases in the addition of an acetate into the quinone functionality of compound **9**.

Fortunately, as reported in a preliminary communication, modifications to the quinone formation strategy provided a synthesis of the desired natural product.¹⁵ The solution is realized through the incorporation of a chlorine onto the dimethoxyaryl moiety (Scheme 2, $\mathbf{6} \rightarrow \mathbf{12}$). Compound **13** is prepared from **12** in a similar fashion to our initial studies (*cf.* Scheme 1). Interestingly, this dimethoxychloroarene **13** undergoes a regioselective oxidation to an appropriately functionalized chloroquinone which is then hydrolyzed to provide ilimaquinone (**13** \rightarrow **1**).

This successful pathway to (-)-ilimaquinone can now be altered at various intermediates to yield a series of potentially useful structural analogs. For example, as illustrated in Scheme 3, the preparation of analog 16 originates with the synthetic intermediate 12. Hydroboration of the $\Delta^{8,13}$ olefin in **12** followed by oxidative workup yields a 2:1 ratio of epimeric hydroxymethylcontaining substrates (14:17) in 74% yield. Attachment of a linker group to the newly formed C13 hydroxyl group of 14 provides compound 15. The subsequent steps then follow the reaction sequence developed for the natural product (\rightarrow **16**). An analogous sequence was carried out on the epimeric hydroxymethyl product $(17 \rightarrow 19)$. In a similar fashion, compound 13 can be stereoselectively hydroborated in 88% yield to provide 20. After attachment of a linker $(20 \rightarrow 21)$ the quinone functionality is introduced in a straightforward manner to yield ilimaguinone analog 22.

Efforts were also directed toward the synthesis of avarone (2) and related analogs to investigate the role of ilimaquinone's functionality on vesicular trafficking, as well as to determine if related sesquiterpene quinones

^{(10) (}a) Sarma, A. S.; Gayen, A. K. *Tetrahedron Lett.* **1983**, *24*, 3385.
(b) Sarma, A. S.; Chattopadhyay, P. *J. Org. Chem.* **1982**, *47*, 1727. (c) Sharma, A. S.; Gayen, A. K. *Tetrahedron* **1985**, *41*, 4581.

⁽¹¹⁾ For successful preparations of the quinone portion, see: (a) Danheiser, R. L.; Cha, D. D. *Tetrahedron Lett.* **1990**, *31*, 1527. (b) Yadav, J. S.; Upender, V.; Rao, A. V. R. J. Org. Chem. **1992**, *57*, 3242. (c) Reinaud, O.; Capdevielle, P.; Maumy, M. *Tetrahedron* **1987**, *43*, 4167.

⁽¹⁴⁾ Capon, R. J. J. Nat. Prod. 1990, 53, 753.

⁽¹⁵⁾ Bruner, S. D.; Radeke, H. S.; Tallarico, J. A.; Snapper, M. L. *J. Org. Chem.* **1995**, *60*, 1114.



^{*a*} Key: (a) BH₃·DMS, H₂O₂, NaOH; (b) HO₂C(CH₂)₅NHBOC, EDCI, DMAP; (c) PCC, CH₂Cl₂; (d) Ph₃P=CH₂, DMSO; (e) CAN, CH₃CN, H₂O; (f) Pd(Ph₃P)₄, THF, H₂O, NaHCO₃.

Scheme 4^a



^{*a*} Key: (a) Ph₃P=CH₂, DMSO (87%); (b) RhCl₃·H₂O, EtOH, CHCl₃ (84%); (c) CAN, H₂O, AcOH.

share ilimaquinone's cellular activity. While the preparation of compound **23** (Scheme 4) has been described in Sarma's synthesis of **2**, a shortened, enantioselective route is realized with the sequence illustrated in Scheme 4.¹⁶ The desired natural product (**2**) is prepared through a three-step sequence from **23**. Wittig olefination of **23** yields compound **24**; olefin isomerization¹⁷ of **24** followed by CAN oxidation then delivers avarone (**2**). In a related

Chart 1. Phosphatase Activity versus Ilimaquinone Concentration (µM)



fashion, direct CAN oxidation of compound **24** provides isoavarone (**25**), a hybrid structure comprised of ilimaquinone's decalin system and avarone's quinone functionality.

Activity Assay. Since structural modifications may annul ilimaquinone's unique effects on the Golgi apparatus and protein trafficking, an assay to screen structural variants for antisecretory activity is required. A common method for examining the effect of agents on secretory function is through pulse–chase radiolabeling experiments.¹⁸ Choosing to minimize the use of radioactive compounds for safety and environmental reasons, we sought instead to employ an enzymatic assay. Specifically, we adapted a system originally designed in the Crabtree and Schreiber laboratories to study signal transduction events.¹⁹

In this system a plasmid encoding for secreted alkaline phosphatase (AP) under the control of the interleukin-2 NFAT enhancer region is introduced into Jurkat Tlymphocytes.²⁰ These transiently transfected cells can then be selectively activated to express and secrete alkaline phosphatase upon treatment with phorbol ester (PMA) and ionomycin. The amount of alkaline phosphatase secreted is determined spectroscopically by measuring AP-catalyzed hydrolysis of *p*-nitrophenyl phosphate. With this secreted reporter gene system, the effects of various compounds on protein secretion can provide a convenient assessment of secretory function.

Chart 1 represents the measured activity of secreted alkaline phosphatase from activated Jurkat cells treated with various concentrations of (–)-ilimaquinone. The lack of cytotoxicity at the ilimaquinone concentrations tested (\leq 250 μ M) suggests that general inhibition of protein synthesis is not a factor and that these levels of phosphatase activity reflect ilimaquinone's noncytotoxic inhibition of vesicle-mediated trafficking. According to these results, 50% inhibition of AP activity (IC₅₀) is observed at 19 μ M (\pm 3 μ M) ilimaquinone.

In a fashion similar to the study with ilimaquinone, other compounds were examined for inhibition of secreted alkaline phosphatase activity. Chart 2 displays the 50% inhibition concentration (IC_{50}) for ilimaquinone (1), as well as variants of this natural product. The structures of these analogs are illustrated in Figure 2. It is not

⁽¹⁶⁾ Also see: An, J.; Wiemer, D. F. *J. Org. Chem.* **1996**, *61*, 8775. (17) Andrieux, J.; Barton, D. H. R.; Patin, H. *J. Chem. Soc. Perkin Trans. I* **1977**, 359.

⁽¹⁸⁾ For example, see: (a) Ulmer, J. B.; Palade, G. E. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 6992. (b) Misumi, Y.; Misumi, Y.; Miki, K.; Takatsuki, A.; Tamura, G.; Ikehara, Y. *J. Biol. Chem.* **1986**, *261*, 11398. (c) Sampath, D.; Varki, A.; Freeze, H. H. *J. Biol. Chem.* **1992**, *267*, 4440.

⁽¹⁹⁾ Spencer, D. M.; Wandless, T. J.; Schreiber, S. L.; Crabtree, G. R. Science 1993, 262, 1019.

⁽²⁰⁾ The Jurkat cells were modified to constituitively express the T-antigen. This allows for replication of the plasmid through its SV40 promoter (Mr. Peter Belshaw, Harvard University).

2826 J. Org. Chem., Vol. 62, No. 9, 1997



Figure 2. Structural variants of ilimaquinone and related natural products.



surprising that two of the more active compounds tested are chloroquinone **26** (IC₅₀ 7 μ M) and ilimaquinone monoacetate **3** (IC₅₀ 22 μ M), since both of these compounds can readily serve as *in vivo* precursors to ilimaquinone. Because of this possibility, it is unclear whether these variants will lead to useful probes of ilimaquinone's cellular function.

More pertinent to the goal of our studies, however, are the effects of compound **22** (IC₅₀ 8 μ M).²¹ This analog, with all of ilimaquinone's activity and a protected amine group attached through a tether, can serve well as a versatile tool for studying ilimaquinone's cellular interactions. For example, deprotection of the amine group followed by attachment to biotin, a fluorescing group, or a photoaffinity label will provide useful tools for studying ilimaquinone's cellular effects. In fact, preliminary affinity chromatography experiments with **22** immobilized on a solid support have already yielded selective cellular interactions.²²

Conclusions

This work presents three key advancements in a program to decipher ilimaquinone's cellular effects. First,

the applicability of total synthesis toward the construction of ilimaquinone structural variants is demonstrated. Second, the development of a non-radioisotope-based secretion assay to identify agents that effect intracellular protein trafficking is described. Finally, the combination of analog syntheses with the employment of a novel secretion assay has identified a tether-containing ilimaquinone analog (**22**) with all the antisecretory activity of the natural product. With this versatile analog in hand, our future studies are directed at isolating and identifying the target responsible for ilimaquinone's cellular activities.

Experimental Section

General. Starting materials and reagents were purchased from commercial suppliers and used without further purification except the following. THF and Et₂O were distilled over sodium and benzophenone under N₂. DMSO, CH₂Cl₂, and CH₃CN were distilled from CaH₂ under N₂. Cerium ammonium nitrate (CAN, (NH₄)₂Ce(NO₃)₆) was recrystallized from dilute nitric acid. Hexanes and EtOAc were distilled before use.

All oxygen- or moisture-sensitive reactions were carried out under N₂ or Ar in oven-dried (140 °C, \geq 4 h) glassware. Airor moisture-sensitive liquids were transferred by syringe or cannula and introduced into the reaction flasks through rubber septa. Air- or moisture-sensitive solids were transferred in a glovebag. Unless otherwise stated, reactions were stirred with a Teflon-covered stir bar and carried out at rt. Concentration refers to the removal of solvent using a Büchi rotatory evaporator at 40–100 Torr followed by use of a vacuum pump at approximately 1 Torr. Silica gel column chromatography was performed using Baxter brand silica gel 60 Å (230–400 Mesh ASTM). The term "brine" refers to saturated NaCl.

Proton nuclear magnetic resonance spectra (¹H NMR) were measured at 300 MHz on a Varian Unity-300 instrument or at 400 MHz on a Varian Gemini-400 instrument. Chemical shifts are reported in ppm downfield from tetramethylsilane. Infrared spectra (IR) were measured on a Nicolet 510 FT-IR spectrometer and are reported in wavenumbers (cm⁻¹). Optical rotations were measured on a Perkin-Elmer 241 polarimeter using a 1 dm cell. UV–vis absorbances were measured on a Varian Cary 1 E and are reported as λ (ϵ), nm.

Elemental analyses were performed by Robertson Microlit Laboratories, Inc., Madison, NJ. Mass spectral analyses were performed by the Mass Spectrometry Laboratory, University of Illinois at Urbana-Champaign.

⁽²¹⁾ Analog **22** has also been shown to vesiculate the Golgi apparatus in a manner similar to ilimaquinone (C. Jamora and V. Malhotra, UCSD).

⁽²²⁾ Radeke, H. S.; Bruner, S. D.; Digits, C. A.; Snapper, M. L. Manuscript in preparation.

(+)-3α-(6-BOC-aminohexanoic acid ester)ilimaquinone (5). Ilimaquinone (1) (5.0 mg, 0.014 mmol) was dissolved in dry CH₂Cl₂ (1 mL). SeO₂ (0.77 mg, 0.007 mmol) and *t*-BuOOH (3.0 μ L, 0.028 mmol, 90% in H₂O) were added to the stirring solution. The reaction mixture was stirred for 6 h at 25 °C, upon which it was diluted with 1 mL of saturated NH₄-Cl. The organic layer was washed with saturated NH_4Cl (3×) and brine, dried over Na₂SO₄, filtered through Celite, and concentrated to yield a crude oil. Silica gel chromatography (98:2 Et₂O:AcOH) afforded 3-hydroxyilimaquinone (5.0 mg, 94%) as a clear yellow oil: ¹H NMR (CDCl₃, 300 MHz) δ 7.48 (1H, s), 5.86 (1H, s), 4.80 (1H, d, J = 1.5 Hz), 4.73 (1H, d, J =1.5 Hz), 4.23 (1H, s), 3.86 (3H, s), 2.59 (1H, d, J = 13.6 Hz), 2.48 (1H, d, J = 13.7 Hz), 2.00 (1H, d, J = 11.9 Hz), 1.81-1.58 (4H, m), 1.38 (2H, m), 1.25 (6H, s), 0.98 (3H, d, J = 6.4 Hz), 0.88 (3H, s); 13 C NMR (CDCl₃, 100 MHz) δ 181.4, 179.8, 162.7, 159.8, 150.1, 128.8, 101.3, 99.4, 55.5, 50.0, 48.7, 44.1, 41.5, 38.1, 37.9, 31.2, 30.5, 28.6, 27.7, 26.0, 22.2, 18.5; IR (thin film, NaCl) 3436, 2925, 2855, 1653, 1644, 1611, 1456, 1378, 1351, 1260, 1238, 1094, 1039 cm⁻¹; HRMS calcd for $C_{22}H_{30}O_5$ 374.2090, found 374.2093; MS (70 eV) m/z (rel int) 374(M⁺, 4), 356(5), 319(3), 295(3), 281(3), 221(6), 205(7), 189(55), 168-(100), 147(13), 133(18), 119(29), 95(47), 83(37), 69(53), 57(62); $[\alpha]^{25}_{D} = -15 \ (c \ 0.1, \ CHCl_3).$

The 3-hydroxyilimaquinone (5 mg, 0.014 mmol) was dissolved in CH₂Cl₂ (1 mL). DMAP (2.7 mg, 0.014 mmol), 6-BOCaminohexanoic acid (3.2 mg, 0.014 mmol), and EDCI (2.7 mg, 0.014 mmol) were added to the stirring solution. The reaction mixture was allowed to stir for 2 days, the reaction quenched with Et₂O/H₂O, and the mixture acidified with AcOH. The organic solution was separated, washed with saturated NH₄-Cl and brine, and dried over Na₂SO₄. The crude mixture of product and starting material was purified by using silica gel chromatography (gradient of hexanes, Et₂O, and AcOH) to yield 5 (1.7 mg, 84% yield at 75% conversion): ¹H NMR (CDCl₃, 300 MHz) δ 7.49 (1H, s), 5.86 (1H, s), 4.96 (1H, d, J = 1.4 Hz), 4.80 (1H, d, J = 1.5 Hz), 4.73 (1H, d, J = 1.3 Hz), 4.55 (1H, br s), 3.86 (3H, s), 3.12 (2H, dt, J = 6.8, 7.3 Hz), 2.59 (1H, d, J = 13.7 Hz), 2.48 (1H, d, J = 13.9 Hz), 2.36 (2H, t, J = 7.5 Hz), 1.99 (2H, d, J = 10.8 Hz), 1.80 (2H, d, J = 10.8 Hz), 1.67 1.52 (9H, m), 1.43 (9H, s), 1.24 (3H, s), 0.98 (3H, d, J = 6.2Hz), 0.88 (3H, s); 13 C NMR (CDCl₃, 100 MHz) δ 183.7, 181.2, 174.3, 161.1, 159.0, 153.7, 142.2, 113.8, 107.7, 100.2, 79.7, 67.9, $66.6,\ 56.6,\ 56.0,\ 53.8,\ 50.0,\ 46.1,\ 43.1,\ 39.6,\ 39.3,\ 37.3,\ 35.9,$ 34.4, 29.6, 28.2, 26.3, 22.2, 24.2, 17.8, 14.8; IR (thin film, NaCl)-3351, 2926, 2855, 1713, 1698, 1650, 1608, 1557, 1538, 1505, 1456, 1261, 1166 cm⁻¹; HRMS calcd for C₃₃H₅₀NO₈ 588.3536, found 588.3537; MS (70 eV) *m/z* (rel int) 588(M⁺, <1), 477(<1), 374(7), 356(6), 319(6), 207(5), 189(64), 168(100), 140(12), 119(26), 59(26); $[\alpha]^{25}_{D} = +70$ (*c* 0.1, CHCl₃).

(+)-trans-Octahydro-1a-[(3,5-dimethoxyphenyl)methyl]- 1β , $4a\beta$ -dimethyl- 5α -hydroxy-2(1H)-naphthalenone (6a). Liquid NH₃ (100 mL) was distilled from a flask containing Li⁰ into a 250 mL two-neck round bottom flask equipped with a dry ice condenser. Li⁰ (0.212 g, 30.5 mmol) was added to the NH₃, and the resulting blue solution was refluxed for 30 min. The keto alcohol 6 (1.49 g, 7.5 mmol), dissolved in THF (10 mL), was added dropwise over 30 min to the blue solution. After the addition was complete, the reaction mixture was refluxed for an additional 30 min. 2,5-Dimethoxybenzyl bromide (17.0 g, 73.0 mmol) dissolved in THF (15 mL) was added to the stirring solution quickly. The white slurry stirred for 30 min followed by addition of saturated NH₄Cl (50 mL) and dilution with Et₂O (150 mL). The dry ice condenser was replaced with a water condenser, and the NH₃ was allowed to evaporate. Et₂O and HCl (5% aq) were added to the remaining crude solid, the layers were separated, and the aq layer was extracted with $Et_2O(3\times)$. The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated. The resulting orange oil was purified by silica gel chromatography (4:1 hexane:EtOAc) to afford 6a (1.58 g, 57%) as a yellow oil: ¹H NMR (CDCl₃, 400 MHz) δ 6.30 (1H, s), 6.21 (2H, s), 3.74 (6H, s), 3.42 (1H, d, J = 8.2 Hz), 3.32 (1H, d, J = 13.6 Hz), 3.05 (1H, dd, J = 10.2, 5.0 Hz), 2.84 (1H, br s), 2.68 (1H, d, J = 13.0 Hz), 2.51 (1H, ddd, J = 18.6, 12.0, 7.2 Hz),2.44 (1H, dd, J = 9.3, 5.1 Hz), 2.38 (1H, d, J = 13.6 Hz), 2.30 (1H, ddd, J = 17.4, 5.9, 2.6 Hz), 1.98 (1H, ddd, J = 13.3, 6.3, 2.2 Hz), 1.67 (2H, m), 1.34–1.22 (4H, m), 1.12 (3H, s), 0.96 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 216.3, 160.3, 141.1, 121.1, 108.4, 108.2, 98.3, 79.3, 55.0, 45.2, 43.8, 35.1, 34.1, 30.1, 24.0, 23.2, 22.6, 11.5; IR (thin film, NaCl) 3484, 2949, 2867, 2842, 1703, 1665, 1602, 1457, 1425, 1319, 1205, 1148, 1067 cm⁻¹; [α]²⁵_D = +15 (*c* 5.0, EtOAc). Anal. Calcd for C₂₁H₃₀O₄: C, 72.80; H, 8.73. Found: C, 72.80; H, 8.73.

(+)-*trans*-Octahydro-1α-[(3,5-dimethoxyphenyl)methyl]-1β,4aβ-dimethyl-5β-hydroxy-2(1*H*)-naphthalene (7). Sodium hydride (60% oil dispersion; 2.8 g, 0.070 mol) was washed with several portions of anhydrous Et₂O to remove the mineral oil. The flask was purged with N₂ after each washing. The system was then equipped with a rubber septum, a reflux condenser, and a magnetic stir bar. Dry DMSO (56 mL) was introduced, and the reaction mixture was heated at 75 °C for 1 h. The resulting aqua blue methylsulfinyl carbanion was cooled to 0–5 °C. CH₃PPh₃Br (32.2 g, 0.09 mol) in warm DMSO (152 mL) was added through a cannula. The resulting dark yellow solution of the methyltriphenylphosphorane (Ph₃-PCH₂) was stirred at 25 °C for 1 h before being used.

Ph₃PCH₂ (63 mL, 0.4 M, 28 mmol) was transferred with a cannula into a two-neck round bottom flask fitted with a water condenser and a Schlenk adapter. The ketone 6a (0.95 g, 2.8 mmol) was added dropwise to the ylide at rt. Upon completion of addition, the solution was stirred at 75 °C for 4 h and monitored by TLC (1:1 hexane:EtOAc). The reaction was quenched with NH₄Cl (20 mL), and the aq layer was extracted with Et_2O (3×). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by silica gel chromatography (4:1 hexane:EtOAc) to yield compound 7 (510 mg, 60%) as a yellow oil: ¹H NMR (CDCl₃, 400 MHz) δ 6.31 (3H, s), 4.89 (1H, s), 4.64 (1H, s), 3.74 (6H, s), 3.18 (1H, dd, J = 10.2, 5.0 Hz), 2.73 (1H, d, J = 13.6 Hz), 2.56 (1H, d, J = 13.6 Hz), 2.24 (2H, m), 1.75 (1H, dt, J = 12.5, 2.9 Hz), 1.60 (2H, m), 1.51 (2H, m), 1.39-1.17 (3H, m), 0.99 (3H, s), 0.91 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) & 160.4, 153.7, 141.7, 109.7, 109.4, 98.5, 81.5, 55.8, 47.7, 47.5, 43.7, 39.8, 38.1, 31.0, 29.7, 24.8, 23.4, 15.3 cm⁻¹; IR (thin film, NaCl) 3434, 2935, 2862, 1596, 1460, 1428, 1344, 1321, 1293, 1151; $[\alpha]^{25}_{D} = +18$ (*c* 3.5, EtOAc). Anal. Calcd for C₂₂H₃₂O₃: C, 76.70; H, 9.36. Found: C, 76.41; H, 9.13.

(+)-trans-Octahydro-5a-[(3,5-dimethoxyphenyl)methyl]-5β,6β,8aβ-trimethyl-1β-naphthalenol (7c). Compound 7 (10.0 mg, 0.29 mmol), dissolved in CH₂Cl₂ (0.5 mL), was syringed into a flask containing PtO₂ (61 mg, 0.27 mmol). A Schlenk adapter was fitted with a double balloon. The flask was evacuated and flushed with N_2 (3×) and then with H_2 . Hydrogenation was complete in 2 days as determined by NMR. The solution was filtered through a silica gel plug (3 cm). Silica gel chromatography (4:1 hexane:EtOAc) was used to separate the 13:1 mixture of diastereoisomers to provide the major product 7c (8.4 mg, 84%): ¹H NMR (CDCl₃, 400 MHz) δ 6.33 (1H, s), 6.26 (2H, s), 3.77 (6H, s), 3.00 (1H, dd, J = 10.9, 3.5 Hz), 2.63 (1H, d, J = 14.1 Hz), 2.47 (1H, d, J = 14.1 Hz), 1.82 (2H, m), 1.61 (3H, m), 1.32 (6H, m), 1.13 (1H, d, J = 13.8 Hz), 1.12 (1H, d, J = 15.3 Hz), 0.98 (3H, d, J = 6.2 Hz), 0.88 (3H, s), 0.80 (3H, s); 13 C NMR (CDCl₃, 100 MHz) δ 160.0, 141.1, 109.9, 97.7, 80.6, 55.2, 45.8, 43.2, 40.6, 39.4, 36.8, 35.5, 29.9, 26.7, 23.9, 21.6, 17.7, 16.7, 12.6; IR (thin film, NaCl) 3459, 2917, 1596, 1457, 1382, 1287, 1073, 954, 828 cm⁻¹; $[\alpha]^{25}_{D} =$ +2.3 (c 1.5, EtOAc). Anal. Calcd for C₂₂H₃₄O₃: C, 76.26; H, 9.89. Found: C, 76.01; H, 10.17.

(-)-*trans*-Octahydro-5α-[(3,5-dimethoxyphenyl)methyl]-5 β ,6 β ,8a β -trimethyl-1(2*H*)-naphthalenone (7d). Alcohol 7c (167 mg, 0.482 mmol) dissolved in CH₂Cl₂ (5 mL) was added dropwise to a stirring solution of PCC (0.103 g, 0.482 mmol) in CH₂Cl₂ (25.0 mL) at 0 °C. The reaction was monitored by TLC (1:1 hexane:EtOAc) for completion, and after 12 h silica gel was added. The reaction mixture was filtered and concentrated. The resulting oil was purified by passing it through a plug of silica gel (1 cm) that was presaturated with Et₂O to afford compound 7d (152 mg, 92%) as a clear oil: ¹H NMR (CDCl₃, 400 MHz) δ 6.30 (1H, s), 6.20 (2H, s), 3.74 (6H, s), 2.63 (1H, d, J = 13.9 Hz), 2.52 (1H, d, J = 13.9 Hz), 2.11 (3H, m), 1.81 (4H, dd, J = 12.8, 3.0 Hz), 1.35 (5H, m), 1.14 (3H, s), 0.99 (3H, d, J = 7.2 Hz), 0.89 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 216.4, 160.9, 140.9, 123.2, 109.4, 98.1, 55.5, 47.4, 43.7, 42.1, 37.7, 35.5, 32.8, 26.8, 25.8, 22.0, 19.3, 18.3, 16.8; IR (thin film, NaCl) 2962, 1709, 1596, 1596, 1464, 1426, 1187, 1162 cm⁻¹; [α]²⁵_D = -24 (*c* 1.1, EtOAc). Anal. Calcd for C₂₂H₃₂O₃: C, 76.70; H, 9.36. Found: C, 77.80; H, 9.24.

(-)-trans-Octahydro-5α-[(3,5-dimethoxyphenyl)methyl]-5β,6β,8aβ-trimethyl-1(2H)-naphthalene (8). Compound 7d (80 mg, 0.23 mmol), dissolved in DMSO (1.0 mL), was added dropwise to Ph₃PCH₂ (4.0 mL, 0.4 M, 1.6 mmol). The solution was refluxed at 80 °C for 15 h and monitored by TLC (4:1 hexane:EtOAc). Purification with Ag-impregnated silica gel (17%, w/w) chromatography (98:2 hexanes:EtOAc) afforded compound 8 as a clear oil (57 mg, 71%): ¹H NMR (CDCl₃, 400 MHz) δ 6.31 (1H, s), 6.25 (2H, s), 4.41 (1H, t, J = 1.4 Hz), 4.39 (1H, t, J = 1.7 Hz), 3.76 (6H, s), 2.64 (1H, d, J = 13.6 Hz), 2.46 (1H, d, J = 13.6 Hz), 2.32 (2H, td, J = 13.8, 5.0 Hz), 2.09 (1H, d, J = 11.8 Hz), 1.95 (2H, m), 1.59 (1H, qd, J = 13.7, 3.2)Hz), 1.50-1.29 (2H, m), 1.06 (3H, s), 0.99 (3H, d, J = 5.7 Hz), 0.83 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) & 160.1, 160.7, 141.8, 109.5, 103.5, 98.4, 55.9, 48.1, 44.1, 42.2, 40.8, 37.3, 36.4, 33.7, 28.7, 28.0, 23.5, 21.4, 18.4, 17.8; IR (thin film, NaCl) 2924, 2861, 1585, 1457, 1426, 1211, 1155, 1067, 897, 834 cm $^{-1};$ $[\!\alpha]^{25}{}_{\rm D}$ = -40 (*c* 0.1, EtOAc). Anal. Calcd for C₂₁H₃₀O₂: C, 80.21; H, 9.62. Found: C, 80.46; H, 9.62.

(–)-2-Methoxy-6-[(*trans*-octahydro-5ß,6ß,8aß-trimethyl-1(2H)-naphthalenyl)methyl]-2,5-cyclohexadiene-1,4-dione (9). CrO_3 (36.0 mg, 0.36 mmol) dissolved in H₂O (100 μ L) and AcOH (600 μ L) was added dropwise to compound **8** (36.3 mg, 0.114 mmol) in AcOH (600 μ L) at 0 °C. The reaction mixture was monitored by TLC (4:1 hexanes:EtOAc). After 30 min, ice water was added, and the aq layer was extracted with EtOAc ($7 \times$). The combined organic layers were washed with (saturated) NH₄Cl, dried over MgSO₄, filtered, and concentrated. Purification through silica gel chromatography (4:1 hexanes:EtOAc) afforded compound 9 (21.0 mg, 68%): ¹H NMR (CDCl₃, 400 MHz) δ 6.38 (1H, d, J = 4.0 Hz), 5.87 (1H, d, J = 4.0 Hz), 4.43 (1H, t, J = 2.5 Hz), 4.47 (1H, t, J = 1.9Hz), 3.81 (3H, s), 2.56 (1H, d, J = 13.5 Hz), 2.4 (1H, d, J = 13.5 Hz), 2.30 (2H, td, J = 16.0, 4.0 Hz), 2.09 (2H, d, J = 12.1 Hz), 1.88 (2H, d, J = 12.1 Hz), 1.54 (2H, d, J = 11.0 Hz), 1.41-1.14 (4H, m), 1.05 (3H, s), 0.94 (3H, d, J = 6.6 Hz), 0.88 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 209.9, 196.3, 160.7, 145.8, 137.7, 122.1, 108.0, 104.1, 57.3, 50.1, 43.8, 41.3, 38.1, 37.7, 36.0, 33.8, 29.0, 28.4, 23.6, 21.6, 18.7, 17.8; IR (thin film, NaCl) 2936, 1678, 1646, 1596, 1457, 1388, 1325, 1224, 1055, 897 cm⁻¹; HRMS calcd for C₂₂H₃₀O₃ 342.2195, found 342.2180; MS (70 eV) m/z (rel int) 342(6, M⁺), 191(37), 175(12), 151(51), 135(22), 108(28), 95(100), 79(27); $[\alpha]^{25}_{D} = -15$ (*c* 2.0, EtOAc).

(–)-3-Acetyl-6-[(*trans*-decahydro-5ß,6ß,8aß-trimethyl-1(2H)-naphthalenyl)methyl]-2-methoxyhydroquinone (10a). Quinone 9 (8.0 mg, 0.048 mmol) was dissolved in AcOH (400 μ L) saturated with NaOAc. The reaction mixture was stirred at rt under N₂ and monitored by TLC (6:4 hexanes: EtOAc, product $R_f = 0.57$) for consumption of quinone. After 7 days, the reaction mixture was diluted with Et₂O (1 mL) and H₂O (1 mL), and the reaction was quenched with saturated NH₄Cl (1 mL) and 5% citric acid. The organic layer was separated, dried over MgSO₄, filtered, and concentrated. Purification through silica gel chromatography (3:2 hexanes: EtOAc) provided compound 10a as a clear oil (6.0 mg, 86%): ¹H NMR (CDCl₃, 400 MHz) δ 6.4 (1H, s), 5.54 (1H, s), 5.30 (1H, s), 4.42 (2H, t, J = 1.9 Hz), 4.38 (1H, t, J = 1.3 Hz), 3.87 (3H, s), 2.64 (1H, d, J = 14.3 Hz), 2.47 (1H, d, J = 14.5 Hz), 2.32 (3H, s), 2.04 (3H, t, J = 5.9 Hz), 1.85 (2H, m), 1.81 (2H, d, J = 1.5 Hz), 1.46 (1H, d, J = 13.0 Hz), 1.40 (1H, d, J = 8.1Hz), 1.25 (2H, m), 1.04 (3H, s), 0.97 (3H, d, J = 5.7 Hz), 0.87 (1H, m), 0.82 (3H, s); $^{13}\mathrm{C}$ NMR (CDCl₃, 400 MHz) δ 175.4, 160.6, 135.8, 120.7, 117.5, 103.2, 61.7, 48.7, 42.4, 40.7, 37.2, 37.1, 36.7, 33.5, 30.1, 28.8, 28.2, 23.4, 21.4, 21.1, 18.1, 17.9; IR (thin film, NaCl) 3427, 2936, 2856, 1772, 1659, 1514, 1464, 1376, 1332, 1193, 1332, 1056, 1023, 973, 891 cm⁻¹; HRMS calcd for C₂₄H₃₄O₅ 402.2406, found 402.2406; MS (70 eV) *m/z* (rel int) 402(12, M⁺), 360(7), 212(66), 191(26), 170(100), 135(15), 121(20), 95(59), 79(13), 67(11).

(-)-*trans*-Octahydro-5 α -[(2-chloro-3,5-dimethoxyphenyl)methyl]-5 β ,8a β -dimethyl-6 β -(hydroxymethyl)-1naphthalenol (17). Olefin 12 (616 mg, 1.63 mmol) dissolved in THF (5 mL) was cooled to 0 °C. BH₃·SMe₂ (0.96 mL, 10 M, 8.8 mmol) was added dropwise to the cooled solution over 30 min. Once the borane addition was complete, the reaction mixture was heated to reflux. After 3 h the reaction mixture was allowed to cool to rt. H₂O (2.5 mL) and EtOH (10 mL) were added; then after 30 min H₂O₂ (30%, 3.4 mL) and NaOH (39 mL, 1 M) were added. After an additional 1 h, K₂CO₃ (100 mg) was added. The reaction mixture was washed with Et₂O (3×), and the organic layer was dried over Na₂SO₄ and concentrated. The diastereomers were separated by silica gel chromatography (3:2 hexanes:EtOAc) to provide 14 and 17 in an overall yield of 74% (14:17 = 2:1).

17: ¹H NMR (CDCl₃, 300 MHz) δ 6.42 (1H, d, J = 2.7 Hz), 6.33 (1H, d, J = 2.7 Hz), 4.13 (1H, d, J = 11.4 Hz), 3.87 (3H, d, J = 1.2 Hz), 3.80 (3H, d, J = 1.2 Hz), 3.23 (1H, dd, J = 10.3, 5.3 Hz), 3.06 (1H, d, J = 10.5 Hz), 2.93 (1H, d, J = 13.7 Hz), 2.75 (1H, d, J = 14.1 Hz), 1.92–1.65 (6H, m), 1.51–1.17 (7H, m), 1.07 (1H, d, J = 11.5 Hz), 0.93 (3H, s), 0.84 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 158.5, 156.4, 139.4, 109.8, 98.6, 81.1, 66.1, 56.7, 56.1, 47.7, 45.7, 41.9, 41.7, 40.1, 36.5, 30.6, 24.4, 22.9, 22.3, 18.6, 13.2, 13.1; IR (thin film, NaCl) 3404, 2936, 2863, 1591, 1453, 1415, 1202, 1163 cm⁻¹; MS (70 eV) m/z (rel int) 398(7, M²⁺), 396(16, M⁺), 359(3), 314(4), 290(6), 270(3), 251(4), 193(25), 186(100), 175(30), 163(14), 151(14), 133(25), 119(27), 109(58), 95(65), 81(83), 67(54), 55(84), 41(78); [α]²⁵_D = -9.8 (*c* 12.0, CHCl₃).

14: ¹H NMR (CDCl₃, 300 MHz) δ 6.59 (1H, d, J = 2.6 Hz), 6.35 (1H, d, J = 2.6 Hz), 4.02 (1H, dd, J = 9.9, 3.3 Hz), 3.81 (3H, s), 3.74 (3H, s), 3.18 (1H, d, J = 13.9 Hz), 3.15 (1H, dd, J = 10.9, 4.1 Hz), 2.36 (1H, d, J = 13.9 Hz), 2.26 (2H, br s), 1.73–1.66 (3H, m), 1.56 (2H, m), 1.59–1.33 (5H, m), 0.92 (3H, s), 0.91 (3H, s) (partial); ¹³C NMR (CDCl₃, 100 MHz) δ 158.6, 156.2, 140.0, 109.7, 108.3, 98.0, 81.6, 62.1, 56.7, 56.0, 47.6, 44.9, 40.9, 40.4, 39.1, 32.5, 30.7, 24.8, 22.2, 21.1, 19.5, 15.3; IR (thin film, NaCl) 3400, 2960, 2872, 1596, 1458, 1344, 1208, 1162, 1041, 932, 748 cm⁻¹; MS (70 eV) m/z (rel int) 398(2, M²⁺), 396(7, M⁺), 362(1), 221(1), 211(5), 205(24), 193(28), 186(100), 175(32), 163(8), 152(25), 133(12), 121(18), 109(31), 95(26), 81(30), 69(18), 55(29), 43(22); [α]²⁵_D = +7.7 (c 19.0, CHCl₃).

(+)-trans-Decahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-5\beta,8a\beta-dimethyl-6\beta-(hydroxymethyl)-1\betanaphthalenol 6-(N-t-BOC-amino)hexanoate (18). Alcohol 17 (165 mg, 0.42 mmol), 6-(N-t-BOC-amino)hexanoic acid (96 mg, 0.42 mmol), and DMAP (61 mg, 0.50 mmol) were placed in a flask and cooled (0-5 °C). EDCI (120 mg, 0.63 mmol) dissolved in CH₂Cl₂ (4.5 mL) was then added dropwise to the flask. The reaction mixture was stirred for 2 h at 0 °C and then allowed to warm to 25 °C. After 12 h the reaction mixture was guenched with saturated NH₄Cl. The aqueous layer was washed $(2 \times)$ with CH₂Cl₂. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (7:3 hexanes:EtOAc) to yield ester 18 (169 mg, 66%) as a clear yellow oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.41 (1H, d, J = 2.6Hz), 6.31 (1H, d, J = 2.7 Hz), 4.56 (1H, s), 4.42 (1H, dd, J =10.4, 2.2 Hz), 3.87 (2H, m), 3.86 (3H, s), 3.78 (3H, s), 3.11 (2H, dt, J = 6.6, 6.2 Hz), 3.05 (1H, dd, J = 10.8, 4.0 Hz), 2.90 (1H, d, J = 14.3 Hz), 2.78 (1H, d, J = 14.3 Hz), 2.30 (2H, t, J = 7.5 Hz), 1.81-1.47 (11H, m), 1.43 (9H, s), 1.35 (4H, m), 1.07 (2H, d, J = 9.7 Hz), 0.92 (3H, s), 0.90 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 174.7, 158.2, 156.6, 156.5, 139.1, 116.7, 109.6, 98.6, 81.2, 68.1, 56.9, 56.2, 47.8, 42.2, 41.7, 41.6, 41.1, 41.0, 40.1, 36.3, 34.9, 30.7, 30.5, 29.1, 27.0, 25.4, 24.5, 23.1, 22.5, 18.9, 13.1; IR (thin film, NaCl) 3403, 2937, 2865, 1730, 1727, 1707, 1692, 1590, 1454, 1201, 1166 cm $^{-1}$; HRMS calcd for $C_{33}H_{51}$ -NO₇Cl 608.3354, found 608.3352; MS (70 eV) m/z (rel int) 610(42, M²⁺), 608(5, M⁺), 553(88), 555(51), 517(100), 499(71), 472(59), 458(64), 406(25), 192(30), 132(18), 91(23); $[\alpha]^{25}_{D} = +18$ (c 11.0, CHCl₃).

(-)-*trans*-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-6β,8aβ-dimethyl-6α-(hydroxymethyl)-1βnaphthalenol 6-(*N*-*t*-BOC-amino)hexanoate (15b): see compound 18 for similar experimental; ¹H NMR (CDCl₃, 300 MHz) δ 6.52 (1H, d, J = 2.7 Hz), 6.35 (1H, d, J = 2.7 Hz), 4.65 (1H, br s), 4.55 (1H, dd, J = 11.2, 4.2 Hz), 4.23 (1H, t, J = 10.3 Hz), 3.81 (3H, s), 3.74 (3H, s), 3.25 (1H, d, J = 14.4 Hz), 3.20 (1H, dd, J = 11.2, 4.2 Hz), 3.06 (2H, dt, J = 6.5, 6.4 Hz), 2.32 (2H, t, J = 6.8 Hz), 2.29 (1H, d, J = 14.6 Hz), 1.94 (2H, dd, J = 8.8, 3.7 Hz), 1.63–1.44 (9H, m), 1.39 (9H, s), 1.35–1.22 (7H, m), 0.94 (3H, s), 0.90 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 174.2, 158.8, 156.4, 139.6, 116.9, 108.1, 98.4, 81.4, 64.5, 56.8, 56.1, 47.5, 41.5, 41.0, 40.6, 39.0, 34.9, 32.2, 30.8, 30.6, 30.2, 29.1, 28.4, 26.9, 25.3, 22.4, 22.2, 20.8, 19.9, 15.3; IR (thin film, NaCl) 3327, 2924, 2848, 1734, 1652, 1552, 1451, 1262, 1155 cm⁻¹; [α]²⁵_D = -20 (c 2.0, CHCl₃).

(–)-*trans*-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-5\u03c6,8a\u03c6-dimethyl-6\u03c6-(hydroxymethyl)-1\u03c6naphthalenone 6-(N-t-BOC-amino)hexanoate (18c). To a stirring solution of PCC (58.8 mg, 0.26 mmol) in CH_2Cl_2 (8.8 mL) was added alcohol 18 (107.2 mg, 0.18 mmol) dissolved in CH₂Cl₂ (8.8 mL) dropwise. The reaction mixture was stirred for 3 h. The brown mixture was filtered through silica gel, which was prewashed with 1:1 hexanes:EtOAc, to yield the ketone 18c (104 mg, 97%) as a clear yellow oil: ¹H NMR $(CDCl_3, 300 \text{ MHz}) \delta 6.40 (1\text{H}, \text{d}, J = 2.6 \text{ Hz}), 6.26 (1\text{H}, \text{d}, J =$ 2.7 Hz), 4.56 (1H, br s), 4.41 (1H, dd, J = 10.8, 2.4 Hz), 3.86 (2H, m), 3.85 (3H, s), 3.75 (3H, s), 3.11 (2H, dt, J = 6.2, 6.0 Hz), 2.89 (1H, d, J = 14.4 Hz), 2.83 (1H, d, J = 14.5 Hz), 2.60 (1H, dt, J = 14.1, 7.1 Hz), 2.31 (2H, t, J = 7.5 Hz), 2.2 (1H, dd, J = 14.5, 4.8 Hz), 2.05 (2H, m), 1.75 (2H, m), 1.62 (4H, m), 1.51-1.31 (6H, m), 1.43 (9H, s), 1.17 (3H, s), 0.99 (3H, s); ¹³C NMR (CDCl₃, 75 MHz) & 216.1, 174.7, 158.6, 156.7, 138.4, 116.4, 109.7, 98.4, 79.8, 74.7, 67.6, 56.9, 56.1, 49.7, 48.7, 42.7, 42.1, 41.3, 41.1, 38.0, 34.9, 32.1, 30.5, 29.1, 27.0, 25.9, 25.4, 22.8, 22.6, 19.4, 19.3; IR (thin film, NaCl) 3380, 2932, 2865, 1708, 1577, 1451, 1158 cm⁻¹; HRMS calcd for C₃₃H₅₀NO₇Cl 607.3272, found 607.3276; MS (70 eV) m/z (rel int) 609(6, M²⁺), 607(14, M⁺), 533(7), 471(9), 377(7), 348(5), 322(84), 191(41), 186(100), 185(29), 173(30), 163(13), 151(13), 149(31), 147(16), 140(11), 135(28), 132(21), 114(20), 107(16), 85(15), 69(25), 57(92), 55(18); $[\alpha]^{25}_{D} = -3.5$ (*c* 13.0, CHCl₃).

(+)-trans-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]- 5β , $8a\beta$ -dimethyl- 6α -(hydroxymethyl)-6-(N-t-BOC-amino)hexanoate 1(2*H*)-naphthalenone (15c): see compound 18e for similar experimental; ¹H NMR $(CDCl_3, 300 \text{ MHz}) \delta 6.55 (1H, d, J = 2.6 \text{ Hz}), 6.40 (1H, d, J =$ 2.5 Hz), 4.61 (1H, dd, J = 11.2, 5.8 Hz), 4.62 (1H, br s), 4.14 (1H, t, J = 11.8 Hz), 3.84 (2H, m), 3.78 (3H, s), 3.28 (1H, d, J)= 14.3 Hz), 3.09 (2H, dt, J = 6.1, 6.0 Hz), 2.54 (1H, dd, J = 10.0, 6.0 Hz), 2.38 (1H, d, J = 14.6 Hz), 2.32 (2H, t, J = 7.0 Hz), 2.23 (1H, d, J = 14.0 Hz), 2.00 (2H, br s), 1.78-1.56 (10H, m), 1.42 (9H, s), 1.33 (5H, m), 1.33 (3H, s), 0.99 (3H, s); ¹³C NMR (CDCl₃, 75 MHz) δ 215.3, 174.1, 159.0, 156.6, 139.2, 108.2, 98.6, 64.3, 56.8, 56.2, 50.0, 48.2, 42.1, 41.4, 41.1, 39.0, 37.8, 37.7, 34.9, 30.4, 30.3, 29.0, 28.8, 27.5, 27.0, 26.2, 25.2, 22.2, 21.7, 21.1, 19.7; IR (thin film, NaCl) 3300, 2961, 2930, 1734, 1641, 1598, 1353, 1200, 1133 cm⁻¹; $[\alpha]^{25}_{D} = +2.6$ (*c* 16.0, CHCl₃).

(+)-trans-Octahydro-5a-[(2-chloro-3,5-dimethoxyphenyl)methyl]- 5β , 8a β -dimethyl- 6β -(hydroxymethyl)-1(2H)-naphthalenyl 6-(N-t-BOC-amino)hexanoate (18d). A solution of Ph₃PCH₂ (0.4 M, 1.53 mmol, 3.84 mL) was placed in a round bottom flask. Ketone 18c (103.7 mg, 0.17 mmol) dissolved in DMSO (1.8 mL) was added dropwise to the stirring ylide solution. The reaction mixture was heated to 75 °C for 30 min and then the reaction quenched with saturated NH₄-Cl. The crude reaction mixture was extracted several times with Et_2O (3×). The combined organic layers were washed with saturated NH₄Cl and brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (7:3 hexanes: EtOAc) to afford olefin 18d (30.0 mg, 75%) as a clear oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.39 (1H, d, J = 3.3 Hz), 6.28 (1H, d, J = 2.9 Hz), 4.56 (1H, br s), 4.47 (1H, s), 4.43 (1H, s), 4.41 (1H, dd, J = 10.8, 2.2 Hz), 3.89 (2H, m), 3.85 (3H, s), 3.76 (3H, s), 3.11 (2H, d, J = 6.6, 7.3)Hz), 2.88 (1H, d, J = 14.3 Hz), 2.76 (1H, d, J = 14.5 Hz), 2.30 (2H, t, J = 7.5 Hz), 2.38 (1H, dd, J = 12.7, 5.0 Hz), 2.11 (1H, d, J = 13.0 Hz), 1.91 (2H, d, J = 9.7 Hz), 1.75 (1H, dd, J =12.6, 4.0 Hz), 1.64-1.50 (5H, m), 1.43 (9H, s), 1.38-1.25 (8H, m), 1.19 (1H, d, J = 10.2 Hz), 1.08 (3H, s), 0.92 (3H, s): ¹³C NMR (CDCl₃, 100 MHz) δ 174.7, 160.0, 158.5, 156.4, 139.1, 109.4, 103.9, 98.7, 68.1, 56.8, 56.2, 49.4, 42.5, 42.2, 42.8, 41.1, 40.7, 36.2, 35.0, 33.6, 30.4, 29.1, 28.8, 27.1, 25.9, 25.3, 22.7, 22.5, 19.4, 19.3; IR (thin film, NaCl) 3390, 2934, 2873, 1720, 1592, 1456, 1251, 1173 cm⁻¹; HRMS calcd for C₃₄H₅₂NO₆Cl 605.3479, found 605.3483; MS (70 eV) *m*/*z* (rel int) 607(4, M²⁺), 605(10, M⁺), 459(5), 375(7), 320(21), 189(100), 186(33), 176(23), 147(8), 133(15), 119(10), 107(13), 95(41), 93(12), 69(10), 57(36) 55(8); [α]²⁵_D = +58 (*c* 15.0, CHCl₃).

(-)-trans-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-5 β ,8a β -dimethyl-6 α -(hydroxymethyl)-1(2H)-naphthalenyl 6-(N-t-BOC-amino)hexanoate (15d): see compound 18d for similar experimental; ¹H NMR (CDCl₃, 300 MHz) δ 6.62 (1H, d, J = 2.4 Hz), 6.38 (1H, d, J = 2.5 Hz), 4.66 (1H, dd, J = 11.0, 2.1 Hz), 4.52 (1H, s), 4.50 (1H, s), 4.29 (1H, t, J = 11.2 Hz), 3.85 (3H, s), 3.78 (3H, s), 3.31 (1H, d, J = 14.4 Hz), 3.09 (2H, dt, J = 6.6, 6.1 Hz), 2.35 (1H, d, J =15.1 Hz). 2.32 (1H. d. J = 14.6 Hz). 1.94 (2H. dd. J = 8.8, 3.7 Hz), 1.63-1.44 (9H, m), 1.39 (9H, s), 1.35-1.22 (6H, m), 0.94 (3H, s), 0.90 (3H, s); $^{13}\mathrm{C}$ NMR (CDCl₃, 100 MHz) δ 174.2, 160.4, 159.0, 156.4, 139.8, 108.0, 103.2, 98.4, 64.4, 57.0, 56.2, 49.6, 41.9, 41.4, 41.2, 41.1, 40.9, 38.8, 35.0, 33.5, 30.9, 30.3, 29.1, 27.0, 25.3, 23.0, 22.8, 20.5, 20.2; IR (thin film, NaCl) 3400, 2960, 2872, 1730, 1710, 1596, 1458, 1344, 1208, 1162, 1041, 932, 748 cm⁻¹; $[\alpha]^{25}_{D} = -60$ (*c* 2.0, CHCl₃).

(+)-2-Methoxy-5-chloro-6-[[trans-octahydro-5ß,8aßdimethyl-6*β*-[[[6-(N-t-BOC-amino)hexanoyl]oxy]methyl]-1(2H)-naphthalenyl]methyl]-1,4-cyclohexadiene-1,4-dione (18e). Arene 18d (9.1 mg, 0.015 mmol) was dissolved in acetonitrile (0.63 mL). CAN (73.6 mg, 0.13 mmol) dissolved in H₂O (0.13 mL) was added dropwise to the stirring solution over 1.25 h. The reaction mixture was allowed to stir for 4 h; then the reaction mixture was partitioned between H₂O and Et₂O. The aqueous layer was separated and washed with Et₂O $(3\times)$. The combined organic layers were washed with brine, filtered, and concentrated. The resulting oil was purified by silica gel chromatography (1:1 hexanes:EtOAc) to yield the quinone 18e (8.5 mg, 94%) as a bright yellow oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.03 (1H, br s), 4.60 (1H, s), 4.51 (2H, d, J = 5.7 Hz), 4.24 (1H, dd, J = 11.2, 2.2 Hz), 3.84 (3H, s), 3.70 (2H, dd, J = 10.5, 9.0 Hz), 3.12 (2H, dt, J = 7.6, 6.0 Hz), 2.84 (1H, d, J = 13.4 Hz), 2.79 (1H, d, J = 13.0 Hz), 2.35 (1H, dd, J = 13.9, 8.2 Hz), 2.28 (2H, t, J = 7.3 Hz), 2.11 (1H, d, J = 9.2Hz), 1.83 (2H, m), 1.66-1.48 (7H, m), 1.43 (9H, s), 1.35-1.25 (6H, m), 1.06 (3H, s), 0.89 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 180.7, 179.4, 174.5, 160.0, 159.8, 156.7, 144.4, 144.0, 110.2, $107.4,\,104.2,\,79.7,\,67.9,\,57.4,\,53.6,\,44.81,\,44.77,\,41.1,\,39.6,\,36.4,$ 34.9, 33.4, 30.5, 30.4, 29.1, 29.0, 27.0, 25.3, 24.1, 21.0, 18.0; IR (thin film, NaCl) 3398, 2929, 2861, 1359, 2341, 1716, 1683, 1653, 1629, 1259, 1163 cm⁻¹; HRMS calcd for C₃₃H₅₀NO₇Cl 607.3273, found 607.3275; MS (70 eV) m/z (rel int) 609(<1, M^{2+}), 607(1, M^+), 533(2), 507(9), 469(2), 375(9), 320(12), 189-(100), 133(19), 95(46), 56(54); $[\alpha]^{25}_{D} = +11$ (c 10, CHCl₃).

(-)-2-Methoxy-5-chloro-6-[[trans-octahydro-5β,8aβdimethyl-6a-[[[6-(N-t-BOC-amino)hexanoyl]oxy]methyl]-1(2H)-naphthalenyl]methyl]-1,4-cyclohexadiene-1,4-dione (15e): see compound 18e for similar experimental; ¹H NMR (CDCl₃, 300 MHz) δ 6.52 (1H, d, J = 2.7 Hz), 6.35 (1H, d, J = 2.7 Hz), 4.65 (1H, br s), 4.55 (2H, dd, J = 11.2, 4.2 Hz), 4.23 (1H, t, J = 10.3 Hz), 3.81 (3H, s), 3.74 (3H, s), 3.25 (1H, d, J = 14.4 Hz), 3.20 (1H, dd, J = 11.2, 4.2 Hz), 3.06 (2H, dt, J = 6.5, 6.4 Hz), 2.32 (2H, t, J = 6.8 Hz), 2.29 (1H, d, J = 14.6 Hz), 2.26 (1H, m), 1.94 (2H, dd, J = 8.8, 3.7 Hz), 1.63-1.44 (9H, m), 1.39 (9H, s), 1.35-1.22 (7H, m), 0.94 (3H, s), 0.90 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 174.2, 158.8, 156.4, 139.6, 116.9, 108.1, 98.4, 81.4, 64.5, 56.8, 56.1, 47.5, 41.5, 41.0, 40.6, 39.0, 34.9, 32.2, 30.8, 30.6, 30.2, 29.1, 28.4, 26.9, 25.3, 22.4, 22.2, 20.8, 19.9, 15.3; IR (thin film, NaCl) 3327, 2924, 2848, 1734, 1652, 1552, 1451, 1262, 1155 cm⁻¹; $[\alpha]^{25}_{D} = -9$ (c 2.0, CHCl₃).

(+)-2-Methoxy-5-hydroxy-6-[[*trans*-octahydro-5 β ,8a β -dimethyl-6 α -[[[6-(*N*-*t*-BOC-amino)hexanoyl]oxy]methyl]-1(2*H*)-naphthalenyl]methyl]-1,4-cyclohexadiene-1,4-dione (16). Pd(PPh)₃ (7.9 mg, 6.9 μ mol) was placed in a flask with THF (0.6 mL) and H₂O (0.6 mL). Chloroquinone 15e

(16.7 mg, 0.03 mmol) in THF (0.6 mL) and NaHCO₃ (1 M, 61 μ L) were added dropwise to the flask. After completion of the addition, the reaction mixture was heated to 80 °C for 10 min; then the reaction was guenched with HCl (5%). The agueous layer was extracted with $Et_2O(3\times)$, and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (1:1:0.001 hexanes:Et₂O:AcOH) to yield quinone 16 (1.2 mg, 7%) as a yellow oil: ¹H NMR (CDCl₃, 300 MHz)- δ 5.87 (1H, s), 4.71 (2H, d, J = 10.5 Hz), 4.56 (1H, br s), 4.51 (1H, s), 4.49 (1H, s), 4.33 (1H, t, J = 11.2 Hz), 3.87 (3H, s), 3.13 (2H, dt, J = 6.5, 6.0 Hz), 2.76 (1H, d, J = 13.0 Hz), 2.27 (2H, t, J = 8.1 Hz), 2.26 (1H, d, J = 13.2 Hz), 2.08 (2H, br s), 1.86–1.52 (10H, m), 1.48 (9H, s), 1.35–1.20 (6H, m), 1.12 (3H, s), 0.94 (3H, s); $^{13}\mathrm{C}$ NMR (CDCl₃, 100 MHz) δ 180.9, 179.5, 174.4, 159.8, 156.6, 145.0, 144.3, 110.2, 107.4, 103.9, 79.7, 64.9, 57.4, 49.2, 44.2, 41.6, 41.4, 36.8, 35.0, 33.4, 33.1, 30.7, 30.4, 29.4, 28.8, 27.0, 24.8, 22.8, 22.1, 21.8, 21.0; IR (thin film, NaCl)-3423, 2963, 2931, 1762, 1684, 1643, 1629, 1589, 1465, 1441, 1230 cm⁻¹; $[\alpha]^{25}_{D} = +10$ (*c* 0.3, CHCl₃).

(-)-2-Methoxy-5-hydroxy-6-[[*trans*-octahydro-5β,8aβdimethyl-6β-[[[6-(*N*-*t*-BOC-amino)hexanoyl]oxy]methyl]-1(2*H*)-naphthalenyl]methyl]-1,4-cyclohexadiene-1,4-dione (19): see quinone 16 for similar experimental; ¹H NMR (CDCl₃, 400 MHz) δ 5.87 (1H, s), 4.58 (1H, br s), 4.51 (1H, d, J = 10.1 Hz), 4.50 (1H, s), 4.47 (1H, s), 4.22 (1H, t, J = 5.9Hz), 3.86 (3H, s), 3.13 (2H, dt, J = 6.7, 5.2 Hz), 2.65 (1H, d, J = 14.1 Hz), 2.45 (1H, d, J = 13.8 Hz), 2.32 (2H, t, J = 7.3 Hz), 2.16 (3H, m), 1.77–1.58 (4H, m), 1.44 (9H, s), 1.41–1.20 (8H, m), 1.07 (3H, s), 0.90 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 181.7, 179.8, 174.2, 159.8, 156.8, 145.8, 145.6, 107.8, 105.7, 100.9, 66.6, 64.1, 57.8, 51.8, 44.2, 44.0, 41.8, 41.4, 40.0, 39.8, 38.0, 36.2, 30.1, 28.4, 27.1, 26.8, 25.8, 24.1, 23.8, 22.0; IR (thin film, NaCl) 3417, 2925, 2866, 1734, 1613, 1353, 1254, 1184, 1120 cm⁻¹; [α]²⁵_D = -10 (*c* 0.1, CHCl₃).

(-)-*trans*-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-5\beta,6\beta,8a\beta-trimethyl-1\beta-(hydroxymethyl)-1(2H)-naphthalene (20). Olefin 13 (77 mg, 0.20 mmol) dissolved in THF (1 mL) was cooled to 0 °C. BH₃·SMe₂ (10 M, 0.031 mL, 0.31 mmol) was added dropwise to the cooled solution over 30 min. After completion of addition the reaction mixture was allowed to stir at 25 °C for 3 h; then NaOH (0.2 mL, 6 M) and EtOH (1 mL) were added. Reaction mixture was cooled again to 0 °C, and 30% H₂O₂ (0.2 mL) was added. After completion of addition the mixture was heated to reflux for 1 h. The reaction was then quenched with water and ice, and the aqueous portion was extracted with $Et_2O(3\times)$. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The crude oil was purified using silica gel chromatography (3:1 hexanes:EtOAc) to yield alcohol 20 (74 mg, 92%) as a clear oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.40 (1H, d, J = 2.7 Hz), 6.37 (1H, d, J = 2.8 Hz), 3.86 (3H, s), 3.78 (3H, s), 3.44 (1H, dd, J = 10.6, 8.1 Hz), 3.20 (1H, dd, J =10.4, 8.4 Hz), 2.79 (1H, d, J = 14.1 Hz), 2.72 (1H, d, J = 14.1 Hz), 1.77 (4H, m), 1.61 (2H, m), 1.41-1.19 (8H, m), 0.98 (3H, s), 0.92 (3H, d, J = 6.4 Hz), 0.81 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) & 158.3, 156.3, 140.1, 109.7, 98.2, 64.3, 56.8, 56.2, 54.4, 50.6, 39.0, 37.92, 37.87, 28.4, 28.3, 27.1, 26.1, 24.2, 24.1, 23.9, 19.2, 18.2, 15.8; IR (thin film, NaCl) 3383, 2936, 2872, 1587, 1454, 1324, 1201, 1161, 1087, 1039, 756 cm⁻¹; HRMS calcd for C₂₃H₃₅O₃Cl 394.2275, found 394.2279; MS (70 eV) *m*/*z* (rel int) $396(M^{2+}, 5)$, $394(M^{+}, 13)$, 209(27), 186(100), 151(12), 135(35), 121(20), 95(28), 67(16); $[\alpha]^{25}_{D} = -15$ (*c* 7.0, CHCl₃).

(-)-*trans*-Octahydro-5α-[(2-chloro-3,5-dimethoxyphenyl)methyl]-5β,6β,8aβ-trimethyl-1β-(hydroxymethyl)naphthyl 6-(*N*-*t*-BOC-amino)hexanoate (21). Alcohol 20 (51 mg, 0.13 mmol), 6-(*N*-*t*-BOC-amino)hexanoic acid (30.0 mg, 0.13 mmol), and DMAP (24 mg, 0.20 mmol) were placed in a flask and cooled to 0 °C. EDCI (37.0 mg, 0.20 mmol) dissolved in CH₂Cl₂ (1.5 mL) was added dropwise. The mixture was stirred at 0 °C for 2 h and then allowed to warm to 25 °C. After 12 h the reaction was quenched with saturated NH₄Cl. The aqueous layer was extracted with CH₂Cl₂ (2×). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (7:3 hexanes:EtOAc) to yield ester 21 (74 mg, 94%) as a clear vellow oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.41 (1H, d, J = 2.6 Hz), 6.37 (1H, d, J = 2.6 Hz), 4.51 (1H, br s), 4.18 (1H, d, J = 5.5 Hz), 4.15 (1H, dd, J = 11.3, 5.1 Hz), 3.97 (2H, dd, J = 10.7, 8.6 Hz), 3.87 (3H, s), 3.80 (3H, s), 3.10 (2H, dt, J = 6.8, 6.6 Hz), 2.79 (1H, d, J = 13.9 Hz), 2.73 (1H, d, J = 14.5 Hz), 2.25 (2H, t, J = 7.3 Hz), 1.79 (1H, br d, J = 7.2 Hz), 1.76–1.59 (7H, m), 1.43 (9H, s), 1.40–1.30 (9H, m), 1.08 (3H, s), 0.92 (3H, d, J = 6.0 Hz), 0.83 (3H, s); ¹³C NMR (CDCl₃, 100 MHz) δ 174.6, 158.3, 156.3, 140.1, 116.8, 109.7, 98.2, 80.0, 66.2, 56.9, 56.2, 50.6, 50.4, 43.2, 42.4, 41.1, 38.9, 37.9, 37.3, 35.0, 30.5, 29.1, 28.2, 27.03, 26.97, 26.3, 25.3, 23.8, 20.3, 19.1, 18.2, 15.7; IR (thin film, NaCl) 3371, 2917, 2855, 1730, 1712, 1688, 1590, 1537, 1503, 1453 cm⁻¹; HRMS calcd for C34H54NO6Cl 607.3639, found 607.3634; MS (70 eV) m/z (rel int) 609(<1, M²⁺), 607(<1, M⁺), 515(1), 446(<1), 365(4), 321(50), 190(78), 151(28), 121(35), 95(34); $[\alpha]^{25}{}_{D} = -30$ (c 3.0, CHCl₃).

(+)-2-Methoxy-5-chloro-6-[[trans-octahydro-5β,6β,8aβtrimethyl-1β-[[[6-(N-t-BOC-6-amino)hexanoyl]oxy]methyl]-5α-naphthyl]methyl]-1,4-cyclohexadiene-1,4-dione (21e). Arene 21 (95 mg, 0.16 mmol) was dissolved in CH₃CN (7.5 mL). CAN (683 mg, 1.25 mmol) dissolved in water (1.25 mL) was added dropwise to the stirring CH₃CN solution over 1.25 h. After 2 h the reaction mixture was diluted with Et₂O and extracted $(5 \times)$. The organic solution was washed with brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (1:1 hexanes:Et₂O) to yield chloroquinone **21e** (85 mg, 92%) as a yellow oil: ¹H NMR (CDCl₃, 300 MHz) δ 6.04 (1H, s), 4.51 (1H, br s), 4.21 (1H, dd, J = 10.4, 3.3 Hz), 3.86 (3H, s), 3.69 (2H, dd, J = 10.6, 3.7 Hz), 3.10 (2H, dt, J = 7.3, 6.0, Hz), 2.79 (1H, d, J = 12.8 Hz), 2.72 (1H, d, J = 12.8 Hz), 2.27 (2H, t, J = 7.3 Hz), 1.80 (2H, br d, J = 10.8 Hz), 1.69-1.53 (8H, m), 1.43 (9H, s), 1.34-1.08 (8H, m), 0.85 (3H, s), 0.83 (3H, s), 0.81 (3H, d, J = 6.4 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 180.8, 179.6, 174.5, 160.1, 156.3, 145.6, 140.1, 107.3, 66.1, 57.4, 54.7, 50.5, 45.9, 41.1, 40.2, 40.1, 39.1, 38.3, 35.0, 30.4, 29.1, 28.4, 27.2, 27.0, 26.3, 25.3, 24.4, 19.5, 17.2, 15.6; IR (thin film, NaCl) 3402, 2930, 2867, 1731, 1713, 1678, 1632, 1456, 1366, 1226, 1168 cm⁻¹; HRMS calcd for C₃₃H₅₀ClNO₇ 607.3275, found 607.3278; MS (70 eV) m/z(rel int) $609(1, M^{2+})$, $607(2, M^{+})$, 551(3), 515(4), 507(18), 497(4), 471(36), 377(5), 366(18), 358(3), 342(76), 322(100), 299(10), 191(40), 175(8), 135(9), 121(11), 109(13), 95(20), 81(8), 69(12), 57(23), 43(14); $[\alpha]^{25}_{D} = +7$ (*c* 5.0, CHCl₃); UVvis (MeOH) 203 (4.62), 288 (4.16) nm.

(+)-2-Methoxy-5-hydroxy-6-[[*trans*-octahydro-5β,6β,-8aβ-trimethyl-1β-[[[6-(N-t-BOC-amino)hexanoyl]oxy] methyl]-5a-naphthyl]methyl]-1,4-cyclohexadiene-1,4-dione (22). Pd(Ph₃P)₄ (20.7 mg, 0.018 mmol) was placed in a flask with THF (2.5 mL) and H₂O (2.5 mL). Chloroquinone 21e (43.6 mg, 0.072 mmol) in THF (2.5 mL) and NaHCO₃ (1 M, 0.16 mL) were added dropwise to the flask. After completion of the addition the reaction mixture was heated to 80 °C for 10 min; then the reaction quenched with HCl (5%). The aqueous layer was extracted with $Et_2O(3\times)$, and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The crude product was purified by silica gel chromatography (1:1:0.001 hexanes:Et₂O:AcOH) to yield quinone 22 (5.2 mg, 16%, 75% conversion) as a yellow oil: ¹H NMR (CDCl₃, 300 MHz) & 7.56 (1H, br s), 5.88 (1H, s), 4.51 (1H, br s), 4.22 (1H, d, J = 10.2 Hz), 3.88 (3H, s), 3.64 (2H, dd, J = 10.5, 8.2 Hz), 3.10 (2H, dt, J = 6.7, 6.6 Hz), 2.55 (1H, d, J = 13.7 Hz), 2.45 (1H, d, J = 13.5 Hz), 2.25 (2H, t, J = 7.1 Hz), 2.00 (2H, d, J = 11.0 Hz), 1.80 (2H, br d, J = 11.7 Hz), 1.60 (4H, m), 1.43 (9H, s), 1.34-1.16 (10H, m), 0.95 (3H, d, J=6.2 Hz), 0.84 (3H, s), 0.80 (3H, s); 13 C NMR (CDCl₃, 100 MHz) δ 180.6, 179.8, 173.2, 159.7, 156.4, 146.6, 139.1, 107.3, 65.3, 58.1, 54.6, 51.1, 48.1, 44.0, 42.1, 40.2, 39.7, 38.0, 35.7, 30.4, 28.8, 26.2, 26.4, 24.5, 23.8, 23.2, 22.2, 19.1, 18.2, 17.5; IR (thin film, NaCl) 3348, 2931, 2862, 1731, 1714, 1694, 1660, 1608, 1453, 1367, 1238, 1170 cm⁻¹; $[\alpha]^{25}_{D} = +10$ (*c* 0.2, CHCl₃); UV-vis (MeOH) 212 (4.24), 287 (3.98) nm (ilimaquinone: 210 (4.35), 288 (4.06) nm).^{3a} Anal. Calcd for C₃₃H₅₁NO₈: C, 67.21; H, 8.72; N, 2.37. Found: C, 67.10; H, 8.69; N, 2.38.

(-)-*trans*-Octahydro- 5α -[(2,5-dimethoxyphenyl)methyl]- 5β , 6β , $8a\beta$ -trimethyl-1-methylenenaphthalene (24). Ke-

Vesicular-Mediated Protein Trafficking

tone 23 (356 mg, 1.0 mmol) in DMSO (5 mL) was added dropwise to a stirring solution of Ph₃PCH₂ (22.5 mL, 0.4 M, 9 mmol) in a 100 mL round bottom flask. The reaction mixture was heated to 75 °C for 5 h and cooled to 25 °C, the reaction quenched with H_2O , and the mixture extracted with $Et_2O(3\times)$. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The resulting oil was purified by silica gel chromatography (99:1 hexanes:Et₂O) to afford 24 (310 mg, 90%) as a white solid: ¹H NMR (CDCl₃, 400 MHz) δ 6.70 (1H, d, J = 3.0 Hz), 6.67 (1H, s), 6.64 (1H, d, J = 2.9 Hz), 4.40 (1H, t, J = 2.4 Hz), 4.36 (1H, t, J = 2.1 Hz), 3.75 (3H, s), 3.71 (3H, s), 2.65 (1H, d, J = 14.1 Hz), 2.58 (1H, d, J = 13.9 Hz), 2.32 (1H, td, J = 14.0, 5.2 Hz), 2.08 (2H, d, J = 16.0 Hz), 1.89 (1H, m), 1.49–1.12 (8H, m), 1.05 (3H, s), 1.00 (3H, d, J= 6.4 Hz), 0.84 (3H, s); ¹³C NMR (CDCl₃, 400 MHz) δ 160.9, 153.5, 153.3, 129.3, 119.4, 111.9, 111.4, 103.3, 55.3, 55.1, 48.7, 42.8, 40.9, 37.8, 37.2, 36.9, 33.8, 29.0, 28.4, 23.8, 21.3, 18.4, 18.2; IR (thin film, NaCl) 2924, 1495, 1457, 1218, 1048, 885, 803, 797, 715 cm⁻¹; mp 74–75 °C; $[\alpha]^{25}_{D} = -50$ (*c* 2.4, EtOAc). Anal. Calcd for C23H34O2: C, 80.65; H, 10.00. Found: C, 80.29; H, 10.16.

Isoavarone (25). CAN (35.5 mg, 0.648 mmol), dissolved in H₂O (500 μ L), was added dropwise to compound 24 (8.0 mg, 0.024 mmol) in CH₃CN (500 μ L). The reaction was monitored hourly by TLC (95:5 hexanes:Et₂O), and after 5 h, the reaction mixture was diluted with H₂O (2 mL) and Et₂O (2 mL). The reaction mixture was extracted with Et₂O (2 mL, $3\times$), and the combined organic layers were dried over MgSO₄, filtered, and concentrated. Purification by silica gel chromatography (98:2 hexanes:Et₂O) yielded compound **25** as a red oil (2.8 mg, 57%): ¹H NMR (CDCl₃, 400 MHz) δ 6.76 (1H, s), 6.68 (1H, s), 6.55 (1H, s), 4.45 (2H, br s), 2.58 (1H, d, J = 13.8 Hz), 2.42 (1H, d, J = 1.4 Hz), 2.31 (2H, t, J = 13.0 Hz), 2.08 (2H, d, J = 12.6Hz), 1.89 (2H, d, J = 11.2 Hz), 1.77 (2H, m), 1.25 (3H, s), 0.94 (3H, d, J = 13.9 Hz), 0.86 (3H, br s); ¹³C NMR (CDCl₃, 400 MHz) & 160.3, 148.1, 137.8, 137.2, 128.9, 124.5, 110.6, 104.0, 99.3, 49.6, 37.3, 35.9, 33.5, 30.4, 28.7, 28.1, 23.3, 21.3, 17.6 (partial carbon); IR (thin film, NaCl) 2930, 2867, 1665, 1652, 1476, 1382, 1255, 1092, 890 cm⁻¹; HRMS calcd for C₂₁H₂₈O₂ 312.2089, found 312.2076; MS (70 eV) m/z (rel int) 191(51), 149(35), 109(31), 95(100), 69(41), 59(51), 57(56).

Avarone (2). The olefin **24** (13 mg, 0.038 mmol) was dissolved in ethanol (0.1 mL, 95%) and chloroform (0.1 mL). RhCl₃·H₂O (1 mg, 0.004 mmol) was added to the stirring solution. After the addition the reaction mixture was heated at reflux under N₂ for 2 days. The reaction mixture was cooled to 25 °C, diluted with Et₂O, and filtered through silica gel (2 cm). The filtrate was concentrated to yield avarol dimethyl ether as a clear oil (11 mg, 85%).

CrO₃ (257 mg, 0.47 mmol) in H₂O (1.7 mL) was added dropwise to avarol dimethyl ether (14.4 mg, 0.042 mmol) in THF (1.7 mL) at rt. The reaction was monitored by TLC (95:5 hexanes:EtOAc), and after 1 h H₂O (0 °C) was added. The reaction mixture was extracted with Et₂O (3×), washed with (saturated) NH₄Cl, dried over MgSO₄, filtered, and concentrated. Purification with Ag-impregnated silica gel (20%, w/w) chromatography (95:5 hexanes:EtOAc) afforded avarone (**2**) (7.5 mg, 57%) that was identical in all aspects to the natural product:²³ ¹H NMR (CDCl₃, 400 MHz) δ 6.77 (2H, m), 6.51 (1H, br s), 5.14 (2H, br s), 2.64 (1H, d, *J* = 13.4 Hz), 2.43 (1H, d, *J* = 13.6 Hz), 2.02 (1H, m), 1.84 (3H, q, *J* = 9.7 Hz), 1.66 (1H, t, *J* = 3.3 Hz), 1.62 (1H, t, *J* = 3.3 Hz), 1.53 (3H, s), 1.38 (2H, dt, *J* = 9.9, 3.3 Hz), 1.00 (3H, s), 0.93 (3H, d, *J* = 7.1 Hz), 0.85 (3H, s); IR (thin film, NaCl) 2911, 1651, 1654 cm⁻¹.

(23) Minale, L.; Riccio, R.; Sodano, G. Tetrahedron Lett. 1974, 38, 3401.

Secretion Assay. All plasticware and glassware were presterilized or purchased sterile. Cell culture media was filtered through Nalgene sterile filters with 0.2 μ m nylon membrane filters before use. The plasmid encoding for secreted AP was obtained from the Schreiber laboratory at Harvard University and used with permission. Incubation refers to storing cells in tissue culture flasks with canted necks and vent caps in a CO₂ incubator at 37 °C, 5.0% CO₂, and 100% humidity. Centrifugation, pelleting, or spinning down refers to using a swinging bucket centrifuge at room temperature at 1000 rpm for 10 min and then aspirating the spent media. Cell counts were obtained using a hemacytometer with cells stained with trypan blue (0.4%); counts were done in duplicate and averaged. Cell morphology was monitored using a phasecontrast cell culture light microscope at 40×.

Jurkat cells were incubated in RPMI 1640 media (without phenol red), 10% fetal bovine serum (FBS), and 5% penicillin/ streptomycin. For normal cell maintenance, cells were grown until saturation $(1.5-2.5 \times 10^{6} \text{ cells/mL})$ and then diluted 10fold with fresh media. To run the assay, 1×10^{7} cells were pelleted (amount required for two compounds assayed in duplicate). Cells were rinsed with RPMI 1640 media and resuspended in 500 μ L of RPMI 1640 media. The cells were pipetted into a 4 mm cuvette containing plasmid (10 μ g). Equilibration (20 min, rt) was then followed by electroporation (960 μ F, 300 V, rt). The cells were reequilibrated (20 min, rt), then diluted with unselected media (10.0 mL, RPMI 1640, 10% FBS), and incubated for 48 h. Under these conditions, a 50% viability of cells was obtained. The cells were then pelleted and resuspended in fresh media (4 mL, RPMI 1640, 10% FBS, 5% penicillin/streptomycin).

A range of compound concentrations was introduced into 96-well plates. Unactivated cells ($100 \ \mu$ L, 1.2×10^6 cells/mL) were pipetted into the wells. To activate the cells, ionomycin and PMA (2 μ M and 100 ng/mL concentrations, respectively) were added. The total volume in each well was diluted to 200 μ L with fresh media. The plate was incubated overnight (37 °C, 5% CO₂, 100% humidity) and then heated (68 °C, 1.5 h) to denature sensitive phosphatases. A *p*-nitrophenyl phosphate solution (100 μ L, 1 mg/mL of *p*-nitrophenyl phosphate in 2 M diethanolamine bicarbonate, pH 10.0) was added to the wells of a new plate. The lyzed cells (100 μ L) were added to the corresponding *p*-nitrophenyl phosphate-containing wells and incubated for 12–24 h. The absorption (410 nm) of each well was measured using a microplate spectrophotometer.

Acknowledgment. The National Institutes of Health (CA 66617) and the Massachusetts Department of Public Health are gratefully acknowledged for their support. In addition, we thank Prof. G. Crabtree and Prof. S. L. Schreiber for a gift of their plasmid, as well as Mr. P. Belshaw for assistance in establishing the antisecretory assay. We also thank Prof. S. M. Hecht for supplying three of the natural products examined (**27–29**) and Prof. J. C. Clardy and Prof. P. J. Scheuer for samples of ilimaquinone. Helpful discussions with Dr. R. B. Wellner and Prof. V. Malhotra are also acknowledged.

Supporting Information Available: ¹H NMR spectra for all new compounds (28 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO962292L